Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 2/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.44 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534459 | 0.78 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL631264 | 0.78 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL4510014 | 0.76 | CYP2A6 (0.58) | SMN1; SMN2CYP2A6ASIC3LOXL2BCL2L1 | |
| SCHEMBL14499525 | 0.76 | CYP1A2 (0.46) | CYP2A6CYP1A2ASIC3LOXL2AGXT | |
| SCHEMBL5451360 | 0.76 | CYP2A6 (0.43) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL7242758 | 0.73 | CYP2A6 (0.54) | SMN1; SMN2CYP2A6CYP1A2ASIC3LOXL2 | |
| SCHEMBL6674653 | 0.72 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL16461209 | 0.72 | CYP2A6 (0.58) | CYP2A6CYP1A2ASIC3LOXL2BCL2L1 | |
| SCHEMBL11221971 | 0.72 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL28666644 | 0.71 | CYP2A6 (0.56) | SMN1; SMN2CYP2A6ASIC3LOXL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | SMN1; SMN2 4137/4885CYP2A6 424/4885CYP1A2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.